Gan & Lee and Menarini Advance Bofanglutide in Europe
Beijing, China & Florence, Italy, September 3, 2026 Gan & Lee Pharmaceuticals and The Menarini Group have entered into...
GLP-1 receptor agonist
Advertisement
Ascletis Starts Phase III Trial of Oral GLP-1 Drug
Hong Kong, China, August 30, 2026 Ascletis Pharma Inc. announced that the first participant has been dosed in its...
Pathos AI Partners with AstraZeneca to Advance AZD4241 for ER+ Breast Cancer
NEW YORK, Aug. 4, 2026 Pathos AI announced a collaboration and co-exclusive licensing agreement with AstraZeneca to advance AZD4241,...
4Moving Biotech Targets Synovitis with Intra-Articular GLP-1 Therapy
LILLE & PARIS, France, Aug. 4, 2026 4Moving Biotech (4MB) announced the completion of patient enrollment in the Phase...
Novo Nordisk Secures UK Approval for First Wegovy Weight-Loss Pill
BAGSVÆRD, Denmark, June 11, 2026 Novo Nordisk announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has...
Advertisements
Ascletis Showcases ASC30, ASC37 and ASC39 Obesity Data at ADA 2026
HONG KONG, June 8, 2026 Ascletis Pharma Inc. presented new clinical and preclinical data from its expanding obesity pipeline...
Ambrosia’s AMB-702 Shows Superior Weight Loss in Preclinical GLP-1 Studies
BOULDER, Colorado, June 5, 2026 Ambrosia Biosciences has unveiled promising preclinical data for AMB-702, its novel oral small-molecule GLP-1...
Lilly’s Foundayo Shows Strong Weight Loss Across Menopause
INDIANAPOLIS, Indiana, June 7, 2026 Eli Lilly and Company has announced new data demonstrating that Foundayo® (orforglipron), the only...
Rivus Highlights RV-8451 Muscle-Preserving Obesity Data
CHARLOTTESVILLE, Va., and SOUTH SAN FRANCISCO, Calif., June 5, 2026 Rivus Pharmaceuticals announced new preclinical data for RV-8451, its...
Structure Therapeutics Highlights Aleniglipron Phase 2b Success
SAN FRANCISCO, June 5, 2026 Structure Therapeutics Inc. announced the publication of detailed results from its Phase 2b ACCESS...
Advertisement
